کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
5622750 | 1406188 | 2015 | 10 صفحه PDF | دانلود رایگان |
BackgroundPlasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date.MethodsA total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD.ResultsIncreased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71â0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76â0.98], P = .027) and AD (Aβ1-42: HR = 0.79 [0.69â0.90], P < .001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72â0.96], P = .012).ConclusionOur results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.
Journal: Alzheimer's & Dementia - Volume 11, Issue 3, March 2015, Pages 249-257.e1